Sigilon Therapeutics Announces Clinical Hold on SIG-001 Phase 1/2 Study in Hemophilia A

The following is sourced from a press release from Sigilon Therapeutics. Read the update in its entirety here. The U.S. Food and Drug Administration (FDA) has placed a clinical hold on Sigilon Therapeutics’ phase 1/2 study of SIG-001 in patients with severe or moderately severe hemophilia A.SIG-001 is a cell-based therapy, designed to carry significant amounts […]